Publications by authors named "Edward M Sellers"

78Publications

Opioids: The Painful Public Health Reality.

Clin Pharmacol Ther 2018 06;103(6):924-935

Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.10
Web Search
https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.10
Web Search
http://doi.wiley.com/10.1002/cpt.1074
Publisher Site
http://dx.doi.org/10.1002/cpt.1074DOI Listing
June 2018

Improving the Clinical Pharmacologic Assessment of Abuse Potential: Part 2: Optimizing the Design of Human Abuse Potential Studies.

Authors:
Edward M Sellers

J Clin Psychopharmacol 2018 Apr;38(2):113-118

From the Departments of Pharmacology and Toxicology, Medicine and Psychiatry, University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCP.0000000000000838DOI Listing
April 2018

Improving the Clinical Pharmacologic Assessment of Abuse Potential: Part 1: Regulatory Context and Risk Management.

Authors:
Edward M Sellers

J Clin Psychopharmacol 2018 Feb;38(1):11-18

From the Departments of Pharmacology and Toxicology, Medicine and Psychiatry, University of Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCP.0000000000000835DOI Listing
February 2018

Studies with psychedelic drugs in human volunteers.

Neuropharmacology 2018 11 21;142:116-134. Epub 2017 Nov 21.

CNS Drug Consulting, McLean, VA, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00283908173054
Publisher Site
http://dx.doi.org/10.1016/j.neuropharm.2017.11.029DOI Listing
November 2018

Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users.

Epilepsy Behav 2018 01 15;78:194-201. Epub 2017 Nov 15.

DecisionLine Clinical Research Corporation,(4) Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yebeh.2017.09.008DOI Listing
January 2018

Categorization of Abuse Potential-Related Adverse Events.

Clin Pharmacol Drug Dev 2018 08 11;7(6):569-574. Epub 2017 Oct 11.

Departments of Psychiatry and Surgery, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpdd.394DOI Listing
August 2018

Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users.

J Clin Psychopharmacol 2017 Dec;37(6):675-683

From the *Altreos Research Partners Inc, Toronto, Ontario, Canada; †UCB Pharma, Monheim am Rhein, Germany; ‡UCB Pharma, Raleigh, NC; and §Departments of Pharmacology and Toxicology, Medicine and Psychiatry, University of Toronto and DecisionLine Global Partners Inc, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCP.0000000000000780DOI Listing
December 2017

Psychedelic Drugs as Therapeutics: No Illusions About the Challenges.

Clin Pharmacol Ther 2018 04 24;103(4):561-564. Epub 2017 Aug 24.

CNS Drug Consulting LLC, McLean, Virginia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.776DOI Listing
April 2018

Oral Human Abuse Potential of Oxycodone DETERx (Xtampza ER).

J Clin Pharmacol 2017 04 1;57(4):500-512. Epub 2016 Nov 1.

University of Toronto and DL Global Partners Inc, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.833DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363337PMC
April 2017

Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.

J Clin Psychopharmacol 2016 Aug;36(4):314-23

From the *Altreos Research Partners Inc, Toronto, Ontario, Canada; †Merck & Co., Inc., Kenilworth, NJ; ‡University of Toronto; §DL Global Partners; and ∥INC Research, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCP.0000000000000516DOI Listing
August 2016

Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users.

J Clin Psychopharmacol 2015 Aug;35(4):396-405

From the *Altreos Research Partners, Inc and †Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada; ‡Research and Development, Teva Pharmaceuticals, Netanya, Israel; and §Algorithme Pharma, Laval, Québec; and ∥DL Global Partners Inc and ¶Biopharma Services Inc, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCP.0000000000000347DOI Listing
August 2015

Use of Remifentanil in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent μ-Receptor Antagonist.

J Clin Psychopharmacol 2015 Jun;35(3):242-9

From the *Altreos Research Partners Inc and †Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada; ‡Alkermes, Inc, Waltham, MA; and §DL Global Consulting and ∥Department of Medicine and Psychiatry, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCP.0000000000000320DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415969PMC
June 2015

Claudio A. Naranjo, MD (1945-2014).

Authors:
Edward M Sellers

Clin Pharmacol Ther 2015 Jan 25;97(1):14-5. Epub 2014 Nov 25.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.12DOI Listing
January 2015

Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect.

Neuropsychiatr Dis Treat 2014 26;10:1161-74. Epub 2014 Jun 26.

DL Global Partners, Inc., Toronto, Canada ; University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/NDT.S30713DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079824PMC
July 2014

Human abuse liability evaluation of CNS stimulant drugs.

Neuropharmacology 2014 Dec 30;87:81-90. Epub 2014 Apr 30.

University of Toronto, Toronto, ON, Canada; DL Global Partners Inc, Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2014.04.014DOI Listing
December 2014

Preventing and managing aberrant drug-related behavior in primary care: systematic review of outcomes evidence.

J Opioid Manag 2014 Mar-Apr;10(2):119-34

President and Principal, DL Global Partners, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2014.0201DOI Listing
July 2014

Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.

CNS Drugs 2014 Apr;28(4):361-72

Actelion Pharmaceuticals Ltd, Clinical Pharmacology, Gewerbestrasse 16, 4123, Allschwil, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40263-014-0150-xDOI Listing
April 2014

From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists.

Trends Pharmacol Sci 2013 Oct 13;34(10):560-70. Epub 2013 Sep 13.

InterVivo Solutions Inc, 120 Carlton Street, Toronto, ON M5A 4K2, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tips.2013.08.001DOI Listing
October 2013

Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.

J Psychopharmacol 2013 Sep 19;27(9):808-16. Epub 2013 Jun 19.

DL Global Partners Inc., Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0269881113493364DOI Listing
September 2013

Effects of low-dose opioids on cognitive dysfunction.

J Clin Oncol 2011 Nov 3;29(32):4342-3; author reply 4343-4. Epub 2011 Oct 3.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.38.2309DOI Listing
November 2011

Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone.

Pain Physician 2010 Nov-Dec;13(6):561-73

Kendle Early Stage, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
June 2011

The role of adverse events and related safety data in the pre-market evaluation of drug abuse potential.

Drug Alcohol Depend 2010 Dec;112(3):173-7

Kendle Early Stage - Toronto, 720 King Street West, Toronto, Ontario M5V 2T3, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drugalcdep.2010.07.001DOI Listing
December 2010

New CYP2A6 gene deletion and conversion variants in a population of Black African descent.

Pharmacogenomics 2010 Feb;11(2):189-98

Department of Pharmacology, Room 4326 Medical Sciences Building, 1 King's College Circle, CAMH & University of Toronto, Toronto, ON M5S 1A8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.09.144DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922202PMC
February 2010

Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone.

J Clin Psychopharmacol 2010 Feb;30(1):25-33

Clinical Pharmacology Group, Kendle Early Stage, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCP.0b013e3181c8f088DOI Listing
February 2010

Effect of metabolic blockade on the psychoactive effects of dextromethorphan.

Hum Psychopharmacol 2010 Jan;25(1):71-9

Centre for Addiction and Mental Health, Nicotine Dependence Clinic, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hup.1086DOI Listing
January 2010

A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo.

Pharmacogenomics J 2009 Aug 14;9(4):274-82. Epub 2009 Apr 14.

Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/tpj.2009.11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922203PMC
August 2009

Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent.

Nicotine Tob Res 2008 Aug;10(8):1319-25

The Centre for Addiction and Mental Health and Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14622200802238894DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2896966PMC
August 2008

Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.

J Clin Pharmacol 2007 Dec 25;47(12):1476-88. Epub 2007 Oct 25.

McNeil Pediatrics, Division of McNeil PPC, 420 Delaware Drive, Fort Washington, PA 19034, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0091270007308615DOI Listing
December 2007

Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use.

Carcinogenesis 2007 Oct 13;28(10):2139-42. Epub 2007 Apr 13.

Department of Radiation Oncology, Princess Margaret Hospital-University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgm087DOI Listing
October 2007

Relative abuse potential of opioid formulations in Canada: a structured field study.

J Opioid Manag 2006 Jul-Aug;2(4):219-27

Ventana Clinical Research Corporation, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2006.0034DOI Listing
March 2007

Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking.

Drug Alcohol Depend 2007 Jun 8;89(1):24-33. Epub 2006 Dec 8.

The Centre for Addiction and Mental Health and the Department of Pharmacology, University of Toronto, Canada M5S 1A8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drugalcdep.2006.11.012DOI Listing
June 2007

CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.

Cancer Epidemiol Biomarkers Prev 2006 Oct;15(10):1812-9

Department of Pharmacology, Center for Addiction and Mental Health, University of Toronto, 1 King's College Circle, Toronto, Ontario, Canada M5S 1A8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-05-0723DOI Listing
October 2006

Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics.

Eur J Clin Pharmacol 2006 Jun 28;62(6):481-4. Epub 2006 Apr 28.

Centre for Addiction & Mental Health, and Department of Pharmacology, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00228-006-0113-3
Publisher Site
http://dx.doi.org/10.1007/s00228-006-0113-3DOI Listing
June 2006

Research design strategies to evaluate the impact of formulations on abuse liability.

Drug Alcohol Depend 2006 Jun 22;83 Suppl 1:S52-62. Epub 2006 Mar 22.

Ventana Clinical Research Corporation, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drugalcdep.2006.01.015DOI Listing
June 2006

Use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults.

J Clin Pharmacol 2006 Mar;46(3):345-52

Department of Pharmacology, University of Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0091270005284389DOI Listing
March 2006

Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.

Clin Pharmacol Ther 2005 Mar;77(3):145-58

Department of Pharmacology and Medicine, 1 King's College Circle, University of Toronto, Canada M5S 1A8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clpt.2004.10.011DOI Listing
March 2005

Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.

Pharmacogenetics 2004 Sep;14(9):615-26

Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00008571-200409000-00006DOI Listing
September 2004

Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers.

J Clin Pharmacol 2004 Oct;44(10):1132-42

Avanir Pharmaceuticals, 11388 Sorrento Valley Road, Suite 200, San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0091270004269521DOI Listing
October 2004

Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping.

J Clin Pharmacol 2004 Sep;44(9):966-73

Clinical Pharmacology Research Center, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326-1394, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0091270004268910DOI Listing
September 2004

EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study.

Psychopharmacology (Berl) 2004 Sep;175(3):382-8

Department of Psychiatry, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00213-004-1817-7DOI Listing
September 2004

The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo.

Nicotine Tob Res 2003 Dec;5(6):891-9

Department of Pharmacology, and Centre for Research in Women's Health, University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14622200310001615231DOI Listing
December 2003

Alcohol withdrawal severity is decreased by symptom-orientated adjusted bolus therapy in the ICU.

Intensive Care Med 2003 Dec 14;29(12):2230-2238. Epub 2003 Oct 14.

Departments of Pharmacology, Medicine, and Psychiatry, University of Toronto, Toronto, Ont., Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00134-003-2033-3DOI Listing
December 2003

Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital.

J Clin Psychopharmacol 2003 Jun;23(3):269-80

Psychopharmacology and Dependence Research Unit, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.jcp.0000084031.22282.24DOI Listing
June 2003

Decreasing smoking behaviour and risk through CYP2A6 inhibition.

Drug Discov Today 2003 Jun;8(11):487-93

Department of Pharmacology, Psychiatry, Medicine University of Toronto, Ontario M5T 3A9, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1359-6446(03)02704-1DOI Listing
June 2003

CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence.

Pharmacogenetics 2003 Jun;13(6):321-8

Department of Pharmacology, University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.fpc.0000054090.48725.a2DOI Listing
June 2003

Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro.

Drug Metab Dispos 2003 Jun;31(6):768-72

Department of Pharmacology, University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.31.6.768DOI Listing
June 2003

Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism.

J Pharmacol Exp Ther 2003 Sep 15;306(3):941-7. Epub 2003 May 15.

Department of Pharmacology, University of Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.103.052183DOI Listing
September 2003

Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration.

Mol Pharmacol 2003 Jan;63(1):96-104

Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.63.1.96DOI Listing
January 2003

CYP2A6 genetic variation and potential consequences.

Adv Drug Deliv Rev 2002 Nov;54(10):1245-56

Centre for Addiction and Mental Health, University of Toronto, Toronto M5S 1A8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0169-409x(02)00065-0DOI Listing
November 2002

Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker.

Clin Pharmacol Ther 2002 Aug;72(2):192-9

Clinical Pharmacology Research Center, Department of Medicine, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326-1394, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1067/mcp.2002.126174DOI Listing
August 2002

Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19.

Drug Metab Dispos 2002 Jun;30(6):663-9

Center for Addiction and Mental Health, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.30.6.663DOI Listing
June 2002

Designer drugs that are potent inhibitors of CYP2D6.

J Clin Psychopharmacol 2002 Jun;22(3):330-2

Department of Pharmacology, University of Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00004714-200206000-00015DOI Listing
June 2002

Treatment of codeine dependence with inhibitors of cytochrome P450 2D6.

J Clin Psychopharmacol 2002 Jun;22(3):326-9

Sunnybrook and Women's College Health Sciences Centre, Women's College Campus, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00004714-200206000-00014DOI Listing
June 2002

The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence.

Pharmacogenomics 2002 Mar;3(2):185-99

Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada, M5S 1A8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14622416.3.2.185DOI Listing
March 2002

Inhibition of cytochromes P450 by antifungal imidazole derivatives.

Drug Metab Dispos 2002 Mar;30(3):314-8

Department of Pharmacology, University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.30.3.314DOI Listing
March 2002

Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior.

Ther Drug Monit 2002 Feb;24(1):163-71

Center for Addictions and Mental Health, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00007691-200202000-00026DOI Listing
February 2002

Treatment of the Acute Alcohol Withdrawal State: A Comparison of Four Drugs.

Authors:
Edward M Sellers

Alcohol Health Res World 1995 ;19(1):34-35

Edward M. Sellers, M.D., Ph.D., is a professor of pharmacology, medicine, and psychiatry, University of Toronto, and senior scientist at the Addiction Research Foundation, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875791PMC
January 1995